Evaluating Amicus Therapeutics: Insights From 6 Financial Analysts
Evaluating Amicus Therapeutics: Insights From 6 Financial Analysts
評估Amicus Therapeutics：來自6位金融分析師的見解
6 analysts have expressed a variety of opinions on Amicus Therapeutics (NASDAQ:FOLD) over the past quarter, offering a diverse set of opinions from bullish to bearish.
在過去的一個季度中，有6位分析師對Amicus Therapeutics（納斯達克股票代碼：FOLD）表達了各種看法，從看漲到看跌，提出了各種各樣的觀點。
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
下表簡要介紹了他們最近的評級，展示了過去30天情緒的演變，並將其與前幾個月進行了比較。
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $17.5, a high estimate of $22.00, and a low estimate of $13.00. A decline of 6.67% from the prior average price target is evident in the current average.
分析師通過對12個月目標股價的評估提供了更深入的見解，顯示平均目標價爲17.5美元，最高估計爲22.00美元，低估值爲13.00美元。目前的平均價格比先前的平均目標股價下降了6.67％。
Deciphering Analyst Ratings: An In-Depth Analysis
解密分析師評級：深度分析
The...
通...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。